drugset
drugset / Press release

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

2016-10-26 · Minerva Neurosciences · original minervaneurosciences.com ↗

Roluperidone · results

Supporting Materials: MINERVA NEUROSCIENCES ANNOUNCES POSITIVE DATA FROM SIX-MONTH EXTENSION OF PHASE IIB TRIAL OF MIN-101 MONOTHERAPY IN SCHIZOPHRENIA.pdf 151.2 KB Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

The release as fetched from its publisher. minervaneurosciences.com ↗